‘Rollover’ Trial to Test Breast Cancer Vaccine, BriaVax, in Combo with Yervoy or Keytruda

‘Rollover’ Trial to Test Breast Cancer Vaccine, BriaVax, in Combo with Yervoy or Keytruda
A “rollover” clinical trial of BriaVax — used in combination with Keytruda (pembrolizumab) or Yervoy (ipilimumab) —  will  soon begin to treat women with advanced breast cancer who did not respond to the investigative vaccine alone in a separate clinical study, BriaVax’s developer, BriaCell Therapeutics, reported. Women whose cancers continued to progress will be enrolled in the new Phase

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *